Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...
ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...
2don MSN
The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...
Welcome to this day in history, March 13th.First and foremost, one of the most impactful global events occurred on March 13, 1969, when the United States, ...
Fourteen years after the Fukushima Daiichi meltdown, radiation levels have decreased, but decommissioning efforts remain ...
Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research Collaboration and Option Agreement with ...
J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...
Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback